*Division of Genetics and Development, Toronto Western Research Institute ¶Division of Neurology, University Health Network †Department of Medicine, Division of Neurology, University of Toronto ‡Lyndhurst Centre, Toronto Rehabilitation Institute ∥Division of Neurology, Mount Sinai Hospital, University of Toronto §Division of Neurology, Sam & Ida Ross Memory Clinic, Rotman Research Institute, Baycrest, Toronto, ON, Canada.
Alzheimer Dis Assoc Disord. 2014 Jan-Mar;28(1):95-8. doi: 10.1097/WAD.0b013e318265c104.
Compulsive behaviors in patients with behavioral variant frontotemporal dementia (bvFTD) occur frequently and are challenging to manage. We report three cases of probable bvFTD associated with compulsive behaviors that responded well to treatment with clomipramine at daily dosages varying from 20 to 175 mg. The titration approach involved an initial 10-mg dose that was subsequently increased in 10 mg increments on a weekly basis until symptom relief without intolerable side effects. Our case series supports the consideration for a therapeutic trial with clomipramine in bvFTD when compulsive behavior occurs in these patients. It also highlights the need for further research on pharmacological treatments in bvFTD.
行为变异型额颞叶痴呆（bvFTD）患者常出现强迫行为，且难以管理。我们报告了三例可能的 bvFTD 相关的强迫行为，这些行为对氯米帕明治疗反应良好，每日剂量为 20 至 175 毫克不等。滴定方法包括起始剂量为 10 毫克，随后每周增加 10 毫克，直到症状缓解且无不可耐受的副作用。我们的病例系列支持在这些患者出现强迫行为时考虑使用氯米帕明进行治疗试验。它还强调了在 bvFTD 中进行药理学治疗研究的必要性。
